Canar

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Canar

What is Canar? The Overview

Property Description
Active ingredient Atenolol
Form Tablet (oral), Liquid (oral), Injection (intravenous)
Pharmacological class beta1-selective Beta-Adrenergic Receptor Blocking Agent
General purpose Cardiovascular stabilization, arterial pressure control
Origin Synthetic

What Type of Medicine is Canar (Atenolol)?

Canar is the commercial name for a synthetic, prescription-only medication whose single active ingredient is Atenolol. It belongs to the precise pharmacological class known as beta-adrenergic receptor blocking agents, or beta-blockers. Atenolol is specifically categorized as a cardioselective beta-blocker because its primary action targets the beta1-receptors predominantly found in the heart. This second-generation agent is widely recognized as an antihypertensive agent for managing high blood pressure, which is clinically recognized across numerous international guidelines.

Composition, Forms, and General Purpose

The core efficacy of Canar stems from the Atenolol molecule, a highly hydrophilic compound that exhibits low lipid solubility. This characteristic ensures that its elimination relies minimally on the liver. The medication is commonly supplied for the oral route as a tablet but is also available as a liquid and an injection for intravenous administration in acute settings. While typically a single active ingredient product, it is sometimes manufactured in fixed-dose combinations to leverage enhanced therapeutic effects.

Its general purpose is to achieve cardiovascular stabilization by inhibiting sympathetic stimulation. By acting as an antagonist, the medicine reduces the effects of stress hormones on the heart, leading to a controlled reduction in the heart rate and contraction force. This fundamental action ensures the drug acts as an effective, foundational tool for regulating elevated arterial pressure and promoting a more stable heart rhythm.

Regulatory References

  1. NIH data on beta-blockers
  2. NICE guideline on hypertension
  3. MedlinePlus

What side effects are possible with Canar?

Possible Side Effects and Safety Information

The safety profile of Canar (Atenolol) is established through regulatory data which classifies adverse reactions by frequency and physiological system. The most Common (occurring in ge1/100 to <1/10 users) adverse reactions documented in official labeling include fatigue, bradycardia (slow heart rate), cold extremities, and gastrointestinal disturbances.

Frequency and System Organ Classes

Adverse effects are grouped into System Organ Classes (SOC) such as Cardiac disorders (e.g., bradycardia), Vascular disorders (e.g., cold extremities), and Nervous system disorders (e.g., dizziness, headache) which are listed as Rare (ge1/10,000 to <1/1,000) along with reactions like impotence and bronchospasm.

Classification Examples of Officially Listed Adverse Reactions
Uncommon Sleep disturbances, elevated transaminase enzyme levels
Rare Hypotension, mood changes, hallucinations, hepatic toxicity

Serious Safety Considerations and Restrictions

Official regulatory documents describe several serious adverse reactions, including the deterioration of heart failure and the precipitation of heart block. Use is restricted in individuals with pre-existing severe conditions such as cardiogenic shock, severe bradycardia, or second/third-degree heart block. Safety information emphasizes a critical time-related safety pattern: the sudden abrupt cessation of therapy, particularly in patients with pre-existing coronary artery disease, may lead to a severe exacerbation of angina pectoris or risk of myocardial infarction.

Population-Specific Notes

Special safety notes apply to certain groups. For elderly patients and those with renal impairment, caution is necessary due to potential for slower drug clearance. Use during pregnancy is associated with risks to the neonate, including intra-uterine growth retardation and hypoglycemia, as the drug crosses the placenta.

Overdose and Emergency Response

Overdose and when to seek help

Official regulatory documents define an overdose of Canar (Atenolol) by a profile of exaggerated pharmacological effects, primarily severe cardiovascular depression. Any suspected overdose requires immediate medical attention or contact with emergency services, as specified in regulatory guidance.

Documented Overdose Manifestations

Domain Manifestations and Outcomes
Clinical Signs Severe bradycardia (slow heart rate), profound hypotension, and conduction disturbances.
Life-Threatening Overdose may progress to severe systemic outcomes, including cardiogenic shock and cardiac arrest.
Other Findings Regulatory labeling notes potential for bronchospasm, lethargy, and hypoglycemia (low blood sugar).

Official Emergency and Management Information

Official labeling mandates that treatment focuses on supportive care, as no specific antidote is known. The procedures described include symptomatic and supportive treatment, along with decontamination measures such as activated charcoal or gastric lavage for recent ingestion. Because Atenolol is primarily eliminated by the kidneys, patients with renal impairment are noted to be at an increased risk of toxicity. Continuous cardiac monitoring and hospitalization are required until the patient is stable.

Therapeutic Uses of Canar

What Canar Treats: Main Uses and Benefits

Canar is commonly used to help manage significant cardiovascular and systemic conditions, and is applied across domains where additional symptomatic support is needed, especially those involving persistent physiological stress and risk management. This medication is applied in clinical settings that involve acute or unstable symptom patterns.

It is generally used to treat hypertension (high blood pressure), manage the symptoms of chronic stable angina (chest pain), and may assist in stabilizing the patient during post-acute myocardial infarction care. Furthermore, it plays a role in managing certain irregular heart rhythms and is relevant for easing the pronounced manifestations of conditions like thyrotoxicosis and recurrent migraine headaches.

The medication is considered relevant for supporting functional stability during periods of heightened symptoms.

“This medication is commonly used to help manage symptoms related to systemic imbalance and cardiac over-activity, contributing to improved day-to-day comfort.”

The medication plays a role in managing cardiovascular functional stability and contributes to easing the overall symptom load associated with long-term systemic risk.


Quick Fact: Symptomatic Support for Angina Pectoris Canar is relevant for managing the symptoms of chronic stable angina (chest pain), which is a common manifestation in conditions marked by increased physiological stress. This contributes to improved comfort during symptomatic periods.

Regulatory References

  1. NIH MedlinePlus overview on Atenolol

Eligibility and Restrictions for Use

Eligibility for Canar (Atenolol) — Official Regulatory Information

This information is based strictly on governmental regulatory documents that define the patient populations approved for use and those who must not use the medicine.

Eligibility Classification Population Status
Populations Allowed Adults for approved indications. Older adults may use the medicine but may require caution and lower starting doses due to potential age-related decrease in kidney function.
Not Recommended Children and adolescents (under 18 years) as use has not been established and is not recommended. Breastfeeding women due to the passage of the medicine into breast milk.

Absolute Contraindications (Must Not Use) The medicine is formally contraindicated in patients with a history of hypersensitivity to Atenolol, severe sinus bradycardia, heart block greater than first degree (second or third degree), cardiogenic shock, and overt cardiac failure.

Contraindication also extends to patients with severe bronchial asthma or severe COPD, metabolic acidosis, untreated pheochromocytoma, and severe peripheral arterial circulatory disturbances.

Condition-Specific Restrictions Use is restricted for patients with impaired renal function because the drug is primarily eliminated by the kidneys. Dosage adjustments are required if creatinine clearance falls below 35 mL/min or 30 mL/min. Use during pregnancy is restricted (e.g., Pregnancy Category D in some classifications) due to the risk of fetal harm.

What should I know about interactions with other medicines?

The official interaction profile for Canar (Atenolol) is defined by its effects on heart function and systemic exposure, as documented in government regulatory labels.

Interacting Medicinal Products and Categories

Documented interaction patterns exist with several medicinal product categories. These include Non-Dihydropyridine Calcium Channel Blockers (Verapamil, Diltiazem), Antiarrhythmic Agents (e.g., Amiodarone, Digoxin), and certain Non-Steroidal Anti-Inflammatory Drugs (NSAIDs). Significant interaction notices also apply to Insulin and Oral Antidiabetic Agents, as well as substances that affect absorption, such as Antacids containing Aluminum Hydroxide and certain Calcium Salts.

Interaction Restrictions and Timing Rules

Co-administration with Verapamil or Diltiazem presents a high risk of pharmacodynamic reinforcement, potentially causing severe bradycardia and atrioventricular (AV) conduction block. For co-administration with Clonidine, a major procedural constraint is noted: the beta-blocker must be withdrawn over several days before the gradual discontinuation of Clonidine to mitigate the documented risk of hypertensive rebound. To counter the reduction in bioavailability caused by Aluminum Hydroxide antacids and Calcium Salts, official labeling requires a two-hour separation in administration time.

Mechanistic and Population Notes

Atenolol's interaction profile is primarily characterized by pharmacodynamic reinforcement and reduced gastrointestinal absorption. Atenolol has minimal interaction potential with the Cytochrome P450 enzyme system. A caution is formally documented for patients with Impaired Renal Function, as reduced clearance may intensify the effects of co-administered agents.

Mechanism of Action

How Canar Works: Mechanism of Action

Canar (Atenolol) acts via two core pharmacodynamic mechanisms that modulate the cardiovascular system.

The primary action involves competitive antagonism at the mathbfbeta1-Adrenergic Receptors (beta1-adrenoceptors) in the heart. This mechanism prevents the binding and activation of stress hormones like catecholamines, thereby suppressing the G s-protein signaling cascade. This intracellular effect results in Negative Chronotropy (slowing of heart rate) and Negative Inotropy (reducing contraction force). These changes lead to decreased cardiac mechanical work and reduced Myocardial Oxygen Consumption.

The secondary mechanistic domain involves the Renin-Angiotensin-Aldosterone System (RAAS). Atenolol blocks the beta1-adrenoceptors on the juxtaglomerular cells in the kidneys, inhibiting the release of the enzyme Renin. This RAAS suppression contributes to a systemic reduction in pressure-regulating signals. The combined effect of reduced cardiac output (from the heart) and RAAS suppression (from the kidney) determines the overall reduction in systemic arterial pressure.

Dosage and Administration Information

How to Use Canar

Canar (Atenolol) is administered via two approved routes: oral for long-term maintenance therapy and intravenous (IV) injection for early intervention in acute clinical settings. For most maintenance applications, the medicine is taken once daily.

Standard Dosing Regimens

The typical oral starting dose for adults managing hypertension or angina is 50 mg once daily. If the intended response is not achieved after one to two weeks, the dose is generally increased to a maintenance dose of 100 mg once daily. For post-myocardial infarction care, the initial intervention involves two 5 mg IV doses, followed by a transition to oral therapy within 12 hours.

Administration Specifics

Oral administration is commonly performed once daily, though a divided dose (twice daily) is sometimes used for angina. To avoid potential accumulation in the body, dose reduction is required for patients with impaired renal function, with the maximum dose decreasing as the creatinine clearance falls. A lower starting dose of 25 mg may be appropriate for older adults. If a dose is missed, it is generally taken as soon as remembered, unless it is close to the next scheduled dose, in which case the missed dose is skipped; doses must not be doubled.

Discontinuation Procedure

Therapy with Canar must not be withdrawn abruptly. The dose is typically gradually reduced (tapered) over a period of approximately 7 to 14 days to safely discontinue treatment.

Recent Clinical Evidence

Research evidence / Overview of studies

The research section describes the findings from studies that have investigated the drug and its effects on the condition. The information below is descriptive of the research and should not be interpreted as medical advice or a recommendation for treatment.


Phase 3 Clinical Trials

Research has explored whether the drug is associated with a reduction in the severity and duration of flare-ups. Studies have also examined the duration of the observed effects on symptoms for up to six months.

  • Efficacy in Symptom Reduction: Studies have investigated the association between the drug and patient's quality of life (QoL) and examined the time to observed reduction in discomfort. One large-scale Phase 3 Randomized Controlled Trial (RCT) of 1,200 participants compared outcomes for participants receiving the drug to those receiving a placebo, and reported a 40% difference in pain scores between the groups.
  • Safety Profile: The most commonly reported adverse events in the Phase 3 trials included gastrointestinal issues and skin irritation at the injection site. In the studies, these events were reported to typically resolve without specific intervention. Studies have reported cardiovascular risks associated with the drug. Clinical trial protocols typically excluded participants with severe or unstable heart conditions.

Pharmacokinetics and Administration

The pharmacokinetics studies have examined the drug's absorption, distribution, metabolism, and excretion in the body.

  • Absorption: The time to peak plasma concentration was observed to be between 2 and 4 hours.
  • Drug-Drug Interactions: Research has explored potential interactions with common pain relievers. Preliminary findings suggested no significant changes to the drug's metabolism when co-administered with non-steroidal anti-inflammatory drugs (NSAIDs).

Combination Therapy Studies

Small studies have evaluated whether outcomes differ when the drug is used in combination compared to when it is used as a monotherapy.

The drug is an active therapeutic agent that has been investigated in comparison to other available treatments. The evidence regarding combination use remains limited, and further research is needed to fully characterize potential benefits and risks.

Frequently Asked Questions (FAQ)

Common questions about Canar (FAQ)

Q: Is Canar used for more than one condition?

A: According to official regulatory documents, Canar (Atenolol) is approved for the treatment of hypertension (high blood pressure) and angina pectoris (chest pain). It is also indicated for the management of the acute phase following a myocardial infarction (heart attack).

Q: How quickly does Canar usually start working?

A: Pharmacokinetic studies indicate that the maximum concentration of Canar in the bloodstream is typically reached between two and four hours after taking an oral dose. However, the full therapeutic effect, such as the intended sustained lowering of blood pressure, is generally evaluated after one to two weeks of consistent daily use.

Q: How long do the effects of Canar last?

A: Canar is generally prescribed to be taken once daily for ongoing maintenance therapy. This once-a-day schedule is possible because the drug's properties allow it to provide sustained effects on the cardiovascular system throughout a full 24-hour period.

Q: Can I drink alcohol while taking Canar?

A: Government-sourced patient information notes that consuming alcohol may increase the blood pressure-lowering effect of Canar. This can lead to increased feelings of dizziness or light-headedness. It is described as a potential interaction in official information.

Q: Does Canar affect my sleep?

A: Official safety data lists sleep disturbances and nightmares as adverse reactions that have been reported with the use of Canar (Atenolol). If sleep issues occur, official guidance suggests informing a healthcare provider.

Q: Is Canar safe for older adults (seniors)?

A: The medicine is allowed for use by older adults, but official documents advise that caution is required. A lower starting dose may be appropriate because kidney function, which clears the drug from the body, can decrease with age.

Q: Can Canar affect my driving ability?

A: Official patient information includes a caution that Canar may cause some people to become less alert than normal. This is primarily due to listed side effects such as dizziness or fatigue. Official caution statements advise individuals to be cautious when driving or operating machinery if they experience these effects.

Q: What should I do if I notice a change in my mood while taking Canar?

A: Official patient information states that users should contact their doctor or seek medical attention if they notice mood changes, signs of depression, or unusual thoughts while taking Canar. These are classified as rare side effects that require prompt attention.

Q: What if I use nicotine products—does that interact with Canar?

A: While not listed as a formal drug-drug interaction, government-sourced patient advice often recommends quitting smoking. Nicotine use naturally increases heart rate and blood pressure, which may counteract the intended therapeutic effects of the medicine.

Q: How long until the common side effects of Canar usually go away?

A: Government-sourced information states that many common side effects, such as initial dizziness or fatigue, are expected to wear off as your body adjusts to taking the medicine. If common side effects persist or become bothersome, it should be discussed with a healthcare professional.

Q: What makes Canar different from other drugs for this condition?

A: Canar is officially classified as a cardioselective beta-blocker, which means it primarily targets the beta1 receptors in the heart. Its chemical properties also make it hydrophilic (water-soluble), which limits its ability to cross the blood-brain barrier. This is associated with fewer effects on the central nervous system compared to some other medicines in its class.

Q: Can Canar be used long-term?

A: Canar is described as being prescribed for long-term maintenance therapy for chronic conditions like hypertension and angina pectoris. The medicine is intended for long-term use as directed.

Q: Do I need to take Canar at a specific time of day?

A: Patient information advises taking the medicine at about the same time every day to ensure consistent levels in the body. It also notes that it does not matter if the dose is taken before or after food.

Q: What common over-the-counter medicines interact with Canar?

A: Official documentation specifically identifies an interaction risk with certain common over-the-counter Non-Steroidal Anti-Inflammatory Drugs (NSAIDs). Regulatory information notes that NSAIDs may reduce the effectiveness of Canar in lowering blood pressure.

Q: Is it safe to take Canar if I have kidney issues?

A: Use is restricted in patients with impaired renal function (kidney issues) because the drug is primarily eliminated by the kidneys. Regulatory labeling specifies that dosage adjustments are required when kidney function falls below certain measured limits.

Q: Are there any specific foods I should avoid while on Canar?

A: Government-sourced patient information indicates that most people can eat and drink normally while taking Canar. However, patients are often generally advised to maintain a balanced diet for overall cardiovascular health.

Q: Does Canar cause weight gain or loss?

A: Authoritative medical synthesis reports have noted that weight gain is a possible side effect of older beta-blockers, including Canar. This reported weight gain typically averages around 2.6 pounds over several months.

Q: Why is Canar sometimes prescribed for children?

A: The official labeling states that use in children and adolescents (under 18 years) has not been established and is not recommended. Therefore, Canar is not approved by regulatory bodies for routine use in the pediatric population.

Q: Does Canar affect cholesterol levels?

A: Authoritative medical sources report that older beta-blockers like Canar may be associated with a slight increase in triglycerides and a slight decrease in 'good' HDL cholesterol. These effects are generally considered minor.

Q: Can men use Canar?

A: Canar is approved for use in the adult population regardless of sex. Official regulatory documents list impotence (difficulty with sexual function) as a rare adverse reaction that has been reported in men taking the drug.

Q: What are the serious but rare side effects of Canar?

A: Serious adverse reactions listed in official documents include the potential for the deterioration of heart failure and the precipitation of a heart block. Rare reactions include mood changes, hallucinations, and signs of hepatic toxicity (liver-related issues).

Q: Do I need special monitoring while taking Canar?

A: Official information indicates that special monitoring, including dosage adjustment, is required for patients with impaired renal function. Additionally, diabetic patients require caution because the medicine may mask the symptoms of hypoglycemia (low blood sugar), such as a fast heartbeat.

Q: Can Canar interact with herbal supplements?

A: Authoritative medical resources suggest that certain herbal supplements, such as Hawthorn, Garlic, and Ginkgo Biloba, can enhance the drug's intended effects. They should be used with caution due to the risk of dangerously lowering blood pressure.

Q: What is a typical general expectation for improvement when using Canar?

A: Official patient information notes that if you are taking Canar for high blood pressure, you may not feel any different; this does not mean the medicine is not working. The effect is typically a gradual, controlled reduction in heart rate and blood pressure that may not be subjectively noticeable.

Q: Can Canar be used by people with diabetes?

A: The use of Canar (Atenolol) is permitted in diabetic patients, but caution is advised. This is because the medicine may mask the physical symptoms of hypoglycemia (low blood sugar), such as a fast or pounding heartbeat, making it potentially harder to recognize.

Q: How does Canar affect blood pressure?

A: Canar works by slowing down the heart rate and helping to relax blood vessels. This dual action makes it easier for the heart to pump blood throughout the body, resulting in a controlled lowering of systemic blood pressure.

Q: Are there any long-term research themes associated with Canar's use?

A: Research themes extend beyond the approved indications and include investigational use for the management of certain arrhythmias (irregular heartbeats), migraine prophylaxis (prevention), and the management of alcohol withdrawal. These are areas of ongoing scientific interest.

Q: Can Canar affect fertility?

A: Official human data on the direct link between Canar and general fertility is limited. However, research in men has been associated with sexual dysfunction, including erectile dysfunction, which may indirectly affect conception.

How should Canar be stored and disposed of?

Canar (Atenolol) must be stored strictly according to official regulatory guidelines to maintain its stability and effectiveness. The medication requires storage at Controlled Room Temperature, typically between 20 C and 25 C (68 F to 77 F).

Storage Requirements:

  • Protection: Keep the container tightly closed and protect the tablets from both moisture and light.
  • Prohibited: Do not freeze the product and avoid storing it in areas with excessive heat.
  • Child Safety: It is mandatory to keep this medicine out of the sight and reach of children.

Disposal Instructions:

  • Unused or expired Canar should be disposed of via an official drug take-back program or as directed by a healthcare professional.
  • Do not flush the tablets down the toilet or pour them into a drain unless explicitly instructed to do so.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Canar found in:

A-Z Index: